NCT03333447View on ClinicalTrials.gov

Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

September 13, 2017

Study Completion Date

December 27, 2018

Conditions
Gaucher Disease, Type 1MRI
Interventions
OTHER

MRI

Trial Locations (1)

92110

Beaujon Hospital, Clichy

Sponsors

Lead Sponsor

CEN Biotech

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

BioClinica, Inc.

INDUSTRY

collaborator

Takeda

INDUSTRY

lead

CEN Biotech

INDUSTRY

NCT03333447 - Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa) | Biotech Hunter | Biotech Hunter